A1.08 New treatments and early diagnosis for Alzheimer’s disease

Alzheimer's disease is the most common form of dementia, which is estimated to affect between 21 and 47 million people worldwide. The most important risk factor for AD is ageing, with the number of AD patients increasing as average life expectancy rises. Despite heavy investment in R&D in this area, the drugs available only relieve symptoms and do not interfere with the pathophysiological mechanisms of the disease. With this in mind, this project aims to:

• develop new molecules capable of inhibiting the cleavage of the TrkB-FL receptor and demonstrating their ability to effectively treat AD. These molecules must be developed through to pre-clinical tests (IND studies) to allow approval to enter clinical trials;
• the development of a diagnostic method that allows the disease to be monitored and its treatment to be carried out.

Date Start

Jan. 2, 2023

Date End

Dec. 31, 2025